Serotype changes and drug resistance in invasive pneumococcal diseases in adults after vaccinations in children, Japan, 2010–2013

Emerging Infectious Diseases

Volumn 21, Issue 11, 2015, Pages 1956-1965

  Ubukata, Kimiko ^a   Chiba, Naoko ^a   Hanada, Shigeo ^b   Morozumi, Miyuki ^a   Wajima, Takeaki ^c   Shouji, Michi ^d   Iwata, Satoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFOTAXIME; CEFTRIAXONE; MEROPENEM; PANIPENEM; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; DISEASE SURVEILLANCE; DRUG RESISTANCE; GENE SEQUENCE; GENOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MENINGITIS; PNEUMOCOCCAL INFECTION; PNEUMONIA; REAL TIME POLYMERASE CHAIN REACTION; SEPSIS; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; AGED; ANTIBIOTIC RESISTANCE; GENETICS; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PNEUMOCOCCAL INFECTIONS; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; HUMANS; JAPAN; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROGROUP;

EID: 84944602937     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2111.142029     Document Type: Article

References (40)

1. Alanee SR, McGee L, Jackson D, Chiou CC, Feldman C, Morris AJ, et al. Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis. 2007;45:46-51.http://dx.doi.org/10.1086/518538
2. Muhammad RD, Oza-Frank R, Zell E, Link-Gelles R, Narayan KM, Schaffner W, et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis. 2013;56:e59-67. http://dx.doi.org/10.1093/cid/cis971
3. Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59:1102-6.
4. Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61:816-9.
5. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822-5.
6. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-46. http://dx.doi.org/10.1056/NEJMoa022823
7. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54:893-7.
8. Moore MR, Gertz RE Jr, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197:1016-27. http://dx.doi.org/10.1086/528996
9. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41. http://dx.doi.org/10.1086/648593
10. Rosen JB, Thomas AR, Lexau CA, Reingold A, Hadler JL, Harrison LH, et al. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis. 2011;53:137-43. http://dx.doi.org/10.1093/cid/cir326
11. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59:258-61.
12. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043-51. http://dx.doi.org/10.1001/jama.294.16.2043
13. Gertz RE Jr, Li Z, Pimenta FC, Jackson D, Juni BA, Lynfield R, et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis. 2010;201:770-5. http://dx.doi.org/10.1086/650496
14. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. Emerg Infect Dis. 2013;19:1074-83. http://dx.doi.org/10.3201/eid1907.121830
15. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11:760-8. http://dx.doi.org/10.1016/S1473-3099(11)70090-1
16. Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31:6232-8. http://dx.doi.org/10.1016/j.vaccine.2013.10.032
17. Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, et al. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis. 2014;210:1001-11. http://dx.doi.org/10.1093/infdis/jiu213
18. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59:1066-73. http://dx.doi.org/10.1093/cid/ciu524
19. Chiba N, Morozumi M, Wajima T, Shouji M, Iwata S, Ubukata K, et al. Changes in capsule and drug resistance of pneumococci after introduction of PCV7, Japan, 2010-2013. Emerg Infect Dis. 2014;20:1132-9. http://dx.doi.org/10.3201/eid2007.131485
20. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250-6. http://dx.doi.org/10.1097/01.CCM.0000050454.01978.3B
21. Chiba N, Morozumi M, Ubukata K. Application of the real-time PCR method for genotypic identification of beta-lactam resistance in isolates from invasive pneumococcal diseases. Microb Drug Resist. 2012;18:149-56. http://dx.doi.org/10.1089/mdr.2011.0102
22. Pan XS, Ambler J, Mehtar S, Fisher LM. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996; 40:2321-6.
23. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 21st informational supplement. Vol. 31. Document M100-S21. Wayne (PA): The Institute; 2011.
24. Sakai F, Chiba N, Ono A, Yamagata Murayama S, Ubukata K, Sunakawa K, et al. Molecular epidemiologic characteristics of Streptococcus pneumoniae isolates from children with meningitis in Japan from 2007 through 2009. J Infect Chemother. 2011;17:334-40. http://dx.doi.org/10.1007/s10156-010-0180-3
25. Griffin MR, Zhu Y, Moore MR, Cynthia G, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369:155-63. http://dx.doi.org/10.1056/NEJMoa1209165
26. Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 2014;58:918-24. http://dx.doi.org/10.1093/cid/ciu006
27. Shea KM, Weycker D, Stevenson AE, Strutton DR, Pelton SI. Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US. Vaccine. 2011;29:8042-8. http://dx.doi.org/10.1016/j.vaccine.2011.08.057
28. Taylor S, Marchisio P, Vergison A, Harriague J, Hausdorff WP, Haggard M. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis. 2012;54:1765-73. http://dx.doi.org/10.1093/cid/cis292
29. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455-63. http://dx.doi.org/10.1056/NEJMoa051642
30. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360:244-56 http://dx.doi.org/10.1056/NEJMoa0800836.
31. Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58:6484-9. http://dx.doi.org/10.1128/AAC.03344-14
32. Hampton LM, Pan XS, Ambler J, Mehtar S, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis. 2012;205:401-11. http://dx.doi.org/10.1093/ infdis/jir755
33. Beall B, McEllistrem MC, Gertz RE Jr, Boxrud DJ, Besser JM, Harrison LH, et al. Emergence of a novel penicillin-nonsusceptible, invasive serotype 35B clone of Streptococcus pneumoniae within the United States. J Infect Dis. 2002;186:118-22. http://dx.doi.org/10.1086/341072
34. Song JH, Baek JY, Ko KS. Comparison of capsular genes of Streptococcus pneumoniae serotype 6A, 6B, 6C, and 6D isolates. J Clin Microbiol. 2011;49:1758-64. http://dx.doi.org/10.1128/JCM.02628-10
35. Ko KS, Baek JY, Song JH. Multidrug-resistant Streptococcus pneumoniae serotype 6D clones in South Korea. J Clin Microbiol. 2012;50:818-22. http://dx.doi.org/10.1128/JCM.05895-11
36. Pai R, Gertz RE, Whitney CG, Beall B; Active Bacterial Core Surveillance Team. Clonal association between Streptococcus pneumoniae serotype 23A, circulating within the United States, and an internationally dispersed clone of serotype 23F. J Clin Microbiol. 2005;43:5440-4. http://dx.doi.org/10.1128/JCM.43.11.5440-5444.2005
37. Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. 2007;3:e168. http://dx.doi.org/10.1371/journal.ppat.0030168
38. Ko KS, Baek JY, Song JH. Multidrug-resistant Streptococcus pneumoniae serotype 6D clones in South Korea. J Clin Microbiol. 2012;50:818-22. http://dx.doi.org/10.1128/JCM.05895-11
39. Grabenstein JD, Weber DJ. Pneumococcal serotype diversity among adults in various countries, influenced by pediatric pneumococcal vaccination uptake. Clin Infect Dis. 2014;58:854-64. http://dx.doi.org/10.1093/cid/cit800
40. Lee LH, Gu XX, Nahm M. Towards new broader spectrum pneumococcal vaccines: the future of pneumococcal disease prevention. Vaccines. 2014;2:112-28 http://dx.doi.org/10.3390/vaccines2010112.